Romanos SP

Very excited to share our new story in @NatureCancer! Together w/ Liz, we found a great way to sensitively detect *and* molecularly characterize circulating tumor cells (CTCs) in patients with Multiple Myeloma (MM) and its precursor conditions! #mmsm /1 nature.com/articles/s4301…

🙌 ICYMI: @IrenemGhobrial and @RomanosSP, of @DanaFarber, discussed a novel, single cell, sequencing-based blood test for multiple myeloma called SWIFT-seq that can enable molecular profiling from the blood. 📺 Watch here: buff.ly/kzkF8lB

#ScienceSaturday ❓ Some people with multiple myeloma respond well to CAR T-cell therapy, but others relapse when the cancer finds ways to hide. Why does that happen, and how can we fix it? ➡️ Dr. Fabiana Perna and colleagues at Moffitt Cancer Center, found that one reason is that some myeloma cells don’t have enough of a target protein called BCMA, which CAR T cells need to find and attack the cancer. ➡️ To solve this, the team designed a new kind of CAR T cell that looks for a different target called SEMA4A. This protein is common on myeloma cells—even in patients whose cancer came back after BCMA-CAR T therapy. ➡️ In lab and mouse studies, these SEMA4A-CAR T cells destroyed myeloma cells that regular BCMA-CAR T cells couldn’t reach, showing promise for treating relapsed patients in the future. 🌟 This research could lead to next-generation cell therapies that keep multiple myeloma from coming back and help more patients stay cancer-free longer. @fabianaperna @MoffittNews 🔗 Read more in Cancer Cell: doi.org/10.1016/j.ccel…

@FrancescoMaura4 @JCO_ASCO @MSKCancerCenter @LaStatale @MDAndersonNews @MoffittNews @SylvesterCancer @nyulangone @sangerinstitute @MayoClinic Congrats Francesco and team!

Excited to share new study out today on @JCO_ASCO where we leveraged #WGS to reclassify MGUS and SMM and define the concept of "malignant transformation" @MSKCancerCenter @LaStatale @MDAndersonNews @MoffittNews @SylvesterCancer @nyulangone @sangerinstitute @MayoClinic #mmsm 1/14

🎉Congrats to portfolio company @PredictaBiosci on the close of a $23.4 million #SeriesA and appointment of CEO Brian McKernan. The funding will support development of #diagnostics for blood cancers and autoimmune diseases. 📢 Announcement: businesswire.com/news/home/2025… #PartnerNews

@juanjogrcs @Hemasphere_EHA @somersault1824 Congrats @juanjogrcs @BenDiamondMD @FrancescoMaura4 @TomasJelinekMD! 👏🏻

As we promised, finally the paper is out! 👉Elevated #CTCs reflect high proliferation and genomic complexity in #mmsm onlinelibrary.wiley.com/doi/10.1002/he…

Hi friends, it's #Myeloma Monday! Here are Top Posts of the Week 🧵 1/ @tarekmd91 on joining the faculty at Dana Farber: x.com/tarekmd91/stat…

@tarekmd91 @DanaFarber ❤️

Thrilled to join @DanaFarber as a #multiplemyeloma physician & investigator. I first came here as an international research fellow before moving to NYC for training. 6 years later, I’m back full circle to where it all began to care for patients & drive impactful research #mmsm

@mtmdphd @IrenemGhobrial @LabGhobrial @NatureCancer Thanks for sharing!

SWIFT-seq enables comprehensive single-cell transcriptomic profiling of circulating tumor cells in multiple myeloma & its precursors [Aug 8, 2025] Lightbody, @RomanosSP et al. @IrenemGhobrial - @LabGhobrial @NatureCancer nature.com/articles/s4301… #mmsm #LiquidBiopsy #cactc

@FrancescoMaura4 @NatureGenet @HDMyeloma @SylvesterCancer @MayoClinic @MSKCancerCenter @MSK_DeptOfMed Congrats @FrancescoMaura4 and team! 🎉

Excited to share our new paper, out today on @NatureGenet where we use 421 #WGS to reconstruct the evolutionary history of multiple myeloma #mmsm (🔥🔥). Great collaboration with @HDMyeloma @SylvesterCancer @MayoClinic @MSKCancerCenter @MSK_DeptOfMed ⁦.

🚨 New article alert! 🚨 Check out our last release by @IrenemGhobrial and colleagues on "SWIFT-seq enables comprehensive single-cell transcriptomic profiling of circulating tumor cells in multiple myeloma and its precursors" @DanaFarber 👉nature.com/articles/s4301…

Drs. @IrenemGhobrial, @RomanosSP, and Elizabeth Lightbody at @DanaFarber have developed a blood test that could transform the diagnosis and monitoring of #MultipleMyeloma and its precursor conditions. Press release: bit.ly/4mEUUXB @NatureCancer: go.nature.com/4mG8UAi

Myeloma Paper of the Day, August 10th, Suggested by Robert Orlowski (@Myeloma_Doc) @IrenemGhobrial @NatureCancer oncodaily.com/science/myelom… #OncoDaily #Oncology #Cancer #Health #Medicine #MedTwitter #MedEd #MedOnc #MedNews #MM #Myeloma #SWIFTseq @CancerWorldmag

@NorthTxMSG Thanks for sharing our work!

SWIFT-seq is a powerful option as it can measure the number of CTCs, characterize the genomic alterations of the tumor, estimate the tumor’s proliferative capacity and measure prognostically useful gene signatures in a single test and from a blood sample,” said Dr. @IrenemGhobrial #mmsm dana-farber.org/newsroom/news-…

@juanjogrcs @LabGhobrial Thanks for sharing! 🤓

Through cutting-edge scRNAseq, @LabGhobrial confirms the potential of #CTCs for minimally invasive genomic profiling in #mmsm! 💪🩸 nature.com/articles/s4301…